Biocon Executive Chairperson Kiran Mazumdar-Shaw says she is confident that the company's investment and capacity expansion in Insulin will make the company the top hub for the drug in the next five years. She speaks in an exclusive conversation with Bloomberg's Haslinda Amin. (Source: Bloomberg)
Biocon Executive Chairperson Kiran Mazumdar-Shaw says she is confident that the company's investment and capacity expansion in Insulin will make the company the top hub for the drug in the next five years. She speaks in an exclusive conversation with Bloomberg's Haslinda Amin. (Source: Bloomberg)
<iframe src="https://statesidedaily.com/embed/cluster/70731d3190a9ebefac6965757b7cecf10f314fb9" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Biocon's Mazumdar-Shaw Says Firm On Track To Be Top Insulin Maker"></iframe>
